InvestSMART

Biotron Limited (ASX: BIT) - Announcements

- Current share price for BIT : $0.003

ASX company news and announcements for Biotron Limited (BIT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Biotron Limited (BIT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Biotron Limited (BIT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Biotron Limited (BIT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$8 Appendix 4G and Corporate Governance Statement 19 Aug 2022 3:57PM $0.059 $0.003 fallen by 94.92%
$8 Full Year Statutory Accounts and Appendix 4E 19 Aug 2022 3:56PM $0.059 $0.003 fallen by 94.92%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jul 2022 10:13AM $0.065 $0.003 fallen by 95.38%
$8 POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM 30 May 2022 9:54AM $0.100 $0.003 fallen by 97%
$8 BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS 2 May 2022 10:12AM $0.071 $0.003 fallen by 95.77%
$8 Quarterly Cash Flow Report Appendix 4C 26 Apr 2022 1:28PM $0.076 $0.003 fallen by 96.05%
$8 Quarterly Activities Report 26 Apr 2022 1:28PM $0.076 $0.003 fallen by 96.05%
$8 $1.56M R&D Rebate Received 5 Apr 2022 9:47AM $0.076 $0.003 fallen by 96.05%
$8 BIT225 Effectiveness Against COVID-19 in Animals 17 Mar 2022 11:09AM $0.066 $0.003 fallen by 95.45%
$8 Half Yearly Report and Accounts 23 Feb 2022 4:09PM $0.064 $0.003 fallen by 95.31%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jan 2022 9:20AM $0.075 $0.003 fallen by 96%
$8 Quarterly Appendix 4C Cash Flow Report 28 Jan 2022 8:38AM $0.075 $0.003 fallen by 96%
$8 Update on Biotron HIV-1 And COVID-19 Programs 16 Dec 2021 11:53AM $0.084 $0.003 fallen by 96.43%
$8 Notification of cessation of securities - BIT 6 Dec 2021 10:59AM $0.085 $0.003 fallen by 96.47%
$8 BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS 25 Nov 2021 9:19AM $0.051 $0.003 fallen by 94.12%
$8 Results of Meeting 23 Nov 2021 12:07PM $0.052 $0.003 fallen by 94.23%
$8 Chairman's Address and Presentation to AGM 23 Nov 2021 11:25AM $0.052 $0.003 fallen by 94.23%
$8 COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS 1 Nov 2021 11:19AM $0.048 $0.003 fallen by 93.75%
$8 Quarterly Activities Report 28 Oct 2021 11:19AM $0.051 $0.003 fallen by 94.12%
$8 Quarterly Cash Flow Report 28 Oct 2021 10:22AM $0.051 $0.003 fallen by 94.12%
$8 Annual Report and Notice of Annual General Meeting 20 Oct 2021 12:17PM $0.053 $0.003 fallen by 94.34%
$8 Full Year Statutory Accounts and Preliminary Final Report 27 Aug 2021 1:06PM $0.053 $0.003 fallen by 94.34%
$8 Appendix 4G and Corporate Governance Statement 27 Aug 2021 12:49PM $0.053 $0.003 fallen by 94.34%
$8 Quarterly Activities Report 30 Jul 2021 9:45AM $0.056 $0.003 fallen by 94.64%
$8 Quarterly Appendix 4C Cash Flow Report 30 Jul 2021 9:43AM $0.056 $0.003 fallen by 94.64%

201 - 225 of 594 results

Page 9 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.